NCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
27 trialsNCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT04138628 2026-03-02
TOMBOLA
Aarhus University Hospital
Phase 2 Active not recruiting
NCT04449874 2026-02-12
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Phase 1 Active not recruiting
NCT05542407 2026-01-29
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT05276284 2026-01-14
TEMPLE
Rigshospitalet, Denmark
Phase 1/2 Completed
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT01898117 2025-11-26
Triple-B
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT02862275 2025-10-23
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06680258 2025-09-03
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics
Phase 3 Not yet recruiting
NCT06416436 2025-06-29
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
Phase 1 Withdrawn
NCT03108131 2025-05-28
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03024437 2025-03-20
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Phase 1/2 Terminated
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT05007613 2025-01-01
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT06099418 2024-09-20
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
Nykode Therapeutics ASA
Phase 2 Withdrawn
NCT04167137 2024-05-03
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Synlogic
Phase 1 Terminated
NCT04984811 2024-03-05
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NeoImmuneTech
Phase 2 Active not recruiting
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT04084951 2023-04-14
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Completed
NCT03147040 2022-07-19
GELATO
The Netherlands Cancer Institute
Phase 2 Terminated
NCT03835949 2022-04-01
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
Tracon Pharmaceuticals Inc.
Phase 1 Unknown
NCT03952325 2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2 Terminated